Compare Abeona Therapeutics Inc (ABEO) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gitlab Inc — how do they compare? Abeona Therapeutics Inc trades at $7.41 (market cap $421.19M), while Gitlab Inc trades at $41.13 (market cap $7.11B). The key difference: Gitlab Inc is far larger — about 16.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GTLB | |
|---|---|---|
Market Cap | $421.19M | $7.11B |
Sector | Health | Technology |
52-Week High | $7.45 | $51.04 |
52-Week Low | $4.17 | $19.42 |
Enterprise Value | $276.10M | $5.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
GitLab (GTLB) trades at $40.98, up 0.61% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Revenue grew to $759.25M in 2025, with a high gross margin of 86.74%, but net income remains negative. Recent news highlights AI-driven product launches and Gartner leadership recognition, fueling positive sentiment.
Outlook: Growth prospects are robust due to AI integration and market position, but high valuation (P/E 521.22) and lack of profitability pose risks. Analyst consensus is mixed with a $32.92 price target, suggesting caution despite operational strengths.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
